Search Results - "Notarfranchi, Laura"
-
1
-
2
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Published in Frontiers in oncology (08-07-2021)“…Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as…”
Get full text
Journal Article -
3
CD38 expression by plasma cells in extramedullary multiple myeloma
Published in Haematologica (Roma) (01-04-2024)Get full text
Journal Article -
4
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results
Published in Frontiers in immunology (03-02-2021)“…Maintenance treatment after autologous bone marrow transplantation in multiple myeloma improves the outcome of patients. We designed a phase II clinical trial…”
Get full text
Journal Article -
5
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Published in Oncoimmunology (31-12-2022)“…The humoral and cellular response to SARS-CoV-2 mRNA full vaccination and booster dose as well as the impact of the spike variants, including Omicron, are…”
Get full text
Journal Article -
6
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
Published in Frontiers in immunology (08-01-2021)“…The PD-1/PD-L1 axis has recently emerged as an immune checkpoint that controls antitumor immune responses also in hematological malignancies. However, the use…”
Get full text
Journal Article -
7
-
8
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis
Published in Case reports in hematology (01-01-2018)“…Muscle involvement in AL amyloidosis is a rare condition, and the diagnosis of amyloid myopathy is often delayed and underdiagnosed. Amyloid myopathy may be…”
Get full text
Journal Article -
9
Neurofibromatosis type I and multiple myeloma coexistence: A possible link?
Published in Hematology reports (03-04-2018)“…The association between Neurofibromatosis type I (NF1) and multiple myeloma (MM), a plasma cell, dyscrasia is very rare. Here we put to the attention of the…”
Get full text
Journal Article -
10
Hairy cell leukaemia mimicking multiple myeloma
Published in The lancet oncology (01-03-2019)Get full text
Journal Article -
11
Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
Published in Blood (15-11-2022)Get full text
Journal Article -
12
-
13
PD-L1/PD-1 Pattern of Distribution within Bone Marrow Microenvironment Cells in Patients with Smoldering Myeloma and Active Multiple Myeloma
Published in Blood (05-11-2020)“…Despite the promising results of immune-checkpoint blockade in the treatment of many tumors, the use anti-PDL-1/PD-1 antibodies in multiple myeloma (MM) still…”
Get full text
Journal Article -
14
PSMB4 and PSMD4 Are Correlated with 1q21 Amplification in CD138 + Plasma Cells: New Potential Druggable Targets in Myeloma Patients
Published in Blood (23-11-2021)“…The amplification of the 1q21 (amp1q21) region is one of the most acquired cytogenetic abnormalities (CA) in multiple myeloma (MM) associated with a worse…”
Get full text
Journal Article -
15
Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass
Published in Blood (13-11-2019)“…The identification of risk factors for progression is critical in the clinical management and appropriate follow up of patients with pre-malignant Asymptomatic…”
Get full text
Journal Article -
16
Short-Term Risk for Progression in Patients with Smoldering Multiple Myeloma: The Impact of CD56 Expression
Published in Blood (05-11-2020)“…The identification of risk factors for progression is critical in the clinical management and appropriate follow up of patients with Smoldering Multiple…”
Get full text
Journal Article -
17
Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
Published in Blood (02-11-2023)“…BACKGROUND MRD is an established test in MM clinical trials but not in routine practice. A hindrance to its wider adoption is invasive bone marrow (BM)…”
Get full text
Journal Article -
18
Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
Published in Blood (15-11-2022)Get full text
Journal Article -
19
P-092: Impaired glutamine/glutamate metabolic axis into myeloma microenvironment affects osteoclast formation
Published in Clinical lymphoma, myeloma and leukemia (01-08-2022)Get full text
Journal Article -
20